For a patient on atorvastatin who is experiencing sweating and leg paresthesias and wants to switch to rosuvastatin (Crestor), what dose of rosuvastatin is appropriate—equivalent to 20 mg atorvastatin or a lower dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Atorvastatin 20mg to Rosuvastatin: Dose Recommendation

Switch to rosuvastatin 10 mg, which provides equivalent LDL-lowering to atorvastatin 20 mg while potentially resolving the muscle-related symptoms.

Rationale for Dose Selection

According to the 2018 AHA/ACC cholesterol guidelines, atorvastatin 20 mg is classified as moderate-intensity statin therapy (30-49% LDL-C reduction), while rosuvastatin 10 mg falls in the same moderate-intensity category 1, 2. This makes rosuvastatin 10 mg the appropriate equivalent dose.

The VOYAGER meta-analysis confirms this equivalence with precision: rosuvastatin 10 mg reduces LDL-C by 44% and non-HDL-C by 40%, requiring atorvastatin 29 mg for equivalent LDL-C reduction and 27 mg for equivalent non-HDL-C reduction 3. Since atorvastatin 20 mg falls below these calculated equivalents, rosuvastatin 10 mg actually provides slightly superior lipid-lowering compared to atorvastatin 20 mg.

Why This Switch May Help Your Symptoms

Sweating and leg sensations (paresthesias) on atorvastatin suggest possible statin-related adverse effects. While myalgia is the most commonly reported muscle symptom with statins 4, switching between statins can resolve symptoms in many patients due to differences in:

  • Lipophilicity (atorvastatin is lipophilic; rosuvastatin is hydrophilic)
  • Metabolism pathways (different CYP450 interactions)
  • Individual patient tolerance profiles

The Crestor FDA label shows myalgia occurs in 2.8% of patients on rosuvastatin versus 1.3% on placebo 4, but importantly, individual responses vary significantly between different statins.

Important Monitoring Points

After switching to rosuvastatin 10 mg:

  • Reassess symptoms within 2-4 weeks to determine if leg sensations and sweating resolve
  • Check LDL-C at 4 weeks to confirm adequate lipid control 5
  • If symptoms persist on rosuvastatin 10 mg, consider that they may be unrelated to statin therapy
  • If LDL-C control is inadequate, rosuvastatin can be titrated to 20 mg (high-intensity therapy) 1

Alternative Consideration

If you wanted to start more conservatively due to the adverse effects, rosuvastatin 5 mg is also reasonable, though it provides less LDL-lowering (39% reduction) than your current atorvastatin 20 mg 3. However, rosuvastatin 10 mg is the evidence-based equivalent dose and maintains your current intensity of therapy while potentially eliminating symptoms.

Avoid This Pitfall

Do not use rosuvastatin 20 mg as the equivalent dose—this would be excessive. Rosuvastatin 20 mg is high-intensity therapy (≥50% LDL-C reduction) and equivalent to atorvastatin 70 mg 1, 3. This would represent significant over-treatment and unnecessarily increase the risk of statin-related adverse effects including myopathy 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.